drugset
drugset / Trial / NCT03245307

A Study To Test The Effect Of Apatinib On P450 Enzymes

NCT03245307 ↗

Phase 1 Unknown 20 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2（VEGFR-2）, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro. This study in patients with advanced cancer evaluated the effect of Apatinib on CYP450 function by comparing the pharmacokinetics of CYP-specific probe drugs in the presence and absence of Apatinib. The probes used included Nifedipine (CYP3A specific), warfarin (CYP2C9 specific).

Timeline

Start
2017-08-22
Primary completion
2018-04-30
Completion
2018-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nifedipine Other / unclassified 30 mg Oral
Subject Rivoceranib Small molecule 750 mg Oral
Subject Warfarin Small molecule 3 mg Oral

Indications

No indication recorded.